ReShape Lifesciences Profit Margin

ReShape Lifesciences (RSLS) currently reports a profit margin of 494.66% as of June 2026. That compares with -69.71% in the prior-year period — up 809.5% year over year. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore ReShape Lifesciences's profit margin history and peer comparisons.

ReShape Lifesciences's profit margin increased from -69.71% to 494.66% — a 809.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ReShape Lifesciences's profit margin of 494.66% is higher than the Healthcare sector average of 13.89%. That is roughly 3460.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but ReShape Lifesciences's current 494.66% should be judged against Healthcare norms (sector average: 13.89%) and against RSLS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 494.66%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for ReShape Lifesciences, and consider following RSLS for alerts when major investors trade the stock.